JPWO2019233285A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019233285A5 JPWO2019233285A5 JP2020568229A JP2020568229A JPWO2019233285A5 JP WO2019233285 A5 JPWO2019233285 A5 JP WO2019233285A5 JP 2020568229 A JP2020568229 A JP 2020568229A JP 2020568229 A JP2020568229 A JP 2020568229A JP WO2019233285 A5 JPWO2019233285 A5 JP WO2019233285A5
- Authority
- JP
- Japan
- Prior art keywords
- lvnc
- pharmaceutical composition
- composition according
- ezh2
- cardiomyocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 29
- 229960002855 simvastatin Drugs 0.000 claims description 29
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 29
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 19
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 17
- 230000004217 heart function Effects 0.000 claims description 9
- 230000000747 cardiac effect Effects 0.000 claims description 8
- 230000004060 metabolic process Effects 0.000 claims description 5
- 230000002861 ventricular Effects 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 238000000280 densification Methods 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000022324 non-compaction cardiomyopathy Diseases 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 201000004300 left ventricular noncompaction Diseases 0.000 description 57
- 210000004413 cardiac myocyte Anatomy 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000001973 epigenetic effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101100293244 Mus musculus Mypn gene Proteins 0.000 description 4
- 101150013356 TNNT2 gene Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004153 glucose metabolism Effects 0.000 description 4
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 229960005370 atorvastatin Drugs 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000764260 Homo sapiens Troponin T, cardiac muscle Proteins 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000297 inotrophic effect Effects 0.000 description 2
- 229960001317 isoprenaline Drugs 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- HRDQQHUKUIKFHT-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-methyl-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-propan-2-ylindole-4-carboxamide Chemical compound C1=C2N(C(C)C)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCN(C)CC1 HRDQQHUKUIKFHT-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 201000005943 Barth syndrome Diseases 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940126152 EZH2 methyltransferase inhibitor Drugs 0.000 description 1
- 102100031948 Enhancer of polycomb homolog 1 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100032801 Histone-lysine N-methyltransferase SMYD1 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000920634 Homo sapiens Enhancer of polycomb homolog 1 Proteins 0.000 description 1
- 101000708638 Homo sapiens Histone-lysine N-methyltransferase SMYD1 Proteins 0.000 description 1
- 101000982003 Homo sapiens Myopalladin Proteins 0.000 description 1
- 101000998596 Homo sapiens NADH-cytochrome b5 reductase 2 Proteins 0.000 description 1
- 101000745252 Homo sapiens Plasma membrane ascorbate-dependent reductase CYBRD1 Proteins 0.000 description 1
- 101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 102100026786 Myopalladin Human genes 0.000 description 1
- 102100033168 NADH-cytochrome b5 reductase 2 Human genes 0.000 description 1
- 102100039902 Plasma membrane ascorbate-dependent reductase CYBRD1 Human genes 0.000 description 1
- 102100030702 Polycomb protein SUZ12 Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009511 drug repositioning Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Description
Claims (11)
- EZH2ダウンレギュレーターの治療上有効量を含む、対象における心筋緻密化障害を治療するための医薬組成物。
- 前記心筋緻密化障害は、左心室緻密化障害を含む、請求項1に記載の医薬組成物。
- 前記EZH2ダウンレギュレーターの治療上有効量は、病原性突然変異で引き起こされるEZH2過剰発現を阻害することにより、心筋緻密化障害を治療するのに十分である、請求項1に記載の医薬組成物。
- 前記EZH2ダウンレギュレーターの治療上有効量は、心臓機能を改善することにより、心筋緻密化障害を治療するのに十分である、請求項1に記載の医薬組成物。
- 前記心臓機能は、心臓代謝および心室機能を含む、請求項4に記載の医薬組成物。
- 前記EZH2ダウンレギュレーターは、少なくとも4週間、毎日対象に投与される、請求項1に記載の医薬組成物。
- 前記EZH2ダウンレギュレーターは、スタチンを含む、請求項1に記載の医薬組成物。
- 前記スタチンはシンバスタチンである、請求項7に記載の医薬組成物。
- 前記対象は心筋緻密化障害に罹患しているヒトである、請求項1に記載の医薬組成物。
- 前記EZH2ダウンレギュレーターの治療上有効量は、0.01mg/kg/日から10mg/kg/日の範囲にある、請求項1に記載の医薬組成物。
- 前記シンバスタチンの治療上有効量は、0.01mg/kg/日から10mg/kg/日の範囲にある、請求項8に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862679968P | 2018-06-03 | 2018-06-03 | |
US62/679,968 | 2018-06-03 | ||
PCT/CN2019/088156 WO2019233285A1 (en) | 2018-06-03 | 2019-05-23 | Method for treating non-compaction cardiomyopathy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021525782A JP2021525782A (ja) | 2021-09-27 |
JPWO2019233285A5 true JPWO2019233285A5 (ja) | 2022-04-01 |
JP7387088B2 JP7387088B2 (ja) | 2023-11-28 |
Family
ID=68769233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020568229A Active JP7387088B2 (ja) | 2018-06-03 | 2019-05-23 | 心筋緻密化障害の治療方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11690822B2 (ja) |
EP (1) | EP3801497B1 (ja) |
JP (1) | JP7387088B2 (ja) |
KR (1) | KR20210014126A (ja) |
CN (1) | CN112512519B (ja) |
ES (1) | ES2941777T3 (ja) |
TW (1) | TWI745700B (ja) |
WO (1) | WO2019233285A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4151208A1 (en) * | 2021-09-17 | 2023-03-22 | Universite De Bordeaux | Novel synergistic combinations and methods of uses thereof for treating cancers |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014507429A (ja) * | 2011-02-04 | 2014-03-27 | バイオコピア リミテッド | 心血管疾患の治療のための組成物および方法 |
CA2925242A1 (en) * | 2013-09-23 | 2015-03-26 | President And Fellows Of Harvard College | Allele-specific rna silencing for the treatment of hypertrophic cardiomyopathy |
WO2015077334A2 (en) * | 2013-11-19 | 2015-05-28 | The Brigham And Women's Hospital, Inc. | Therapies for left ventricular non-compaction and dilated cardiomyopathy |
US20160340674A1 (en) * | 2014-02-10 | 2016-11-24 | University Of Rochester | Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases |
US9974767B2 (en) | 2014-07-14 | 2018-05-22 | University Of Washington | Statins in the treatment of muscular dystrophies and myopathies |
CN106963750A (zh) * | 2017-03-30 | 2017-07-21 | 四川省人民医院 | 一种建立心肌致密化不全的动物模型的方法 |
-
2019
- 2019-05-23 CN CN201980038077.9A patent/CN112512519B/zh active Active
- 2019-05-23 WO PCT/CN2019/088156 patent/WO2019233285A1/en unknown
- 2019-05-23 JP JP2020568229A patent/JP7387088B2/ja active Active
- 2019-05-23 ES ES19814175T patent/ES2941777T3/es active Active
- 2019-05-23 US US15/734,315 patent/US11690822B2/en active Active
- 2019-05-23 KR KR1020207036469A patent/KR20210014126A/ko unknown
- 2019-05-23 EP EP19814175.6A patent/EP3801497B1/en active Active
- 2019-05-31 TW TW108119253A patent/TWI745700B/zh active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ljubicic et al. | Transcriptional and post-transcriptional regulation of mitochondrial biogenesis in skeletal muscle: effects of exercise and aging | |
Monti et al. | Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease | |
Katz et al. | Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth | |
Close et al. | Epidermal growth factor receptor expression regulates proliferation in the postnatal rat retina | |
Bell et al. | Hypertrophic effects of calcitonin gene-related peptide (CGRP) and amylin on adult mammalian ventricular cardiomyocytes | |
Tong et al. | Alterations of M2-muscarinic receptor protein and mRNA expression in the urothelium and muscle layer of the streptozotocin-induced diabetic rat urinary bladder | |
Zi et al. | Anxiety administrated by dexmedetomidine to prevent new-onset of postoperative atrial fibrillation in patients undergoing off-pump coronary artery bypass graft | |
Leoni et al. | Chronic heart rate reduction remodels ion channel transcripts in the mouse sinoatrial node but not in the ventricle | |
Ojaimi et al. | Transcriptional basis for exercise limitation in male eNOS-knockout mice with age: heart failure and the fetal phenotype | |
Chernow | Variables affecting outcome in critically ill patients | |
JPWO2019233285A5 (ja) | ||
Carli et al. | Successful treatment with MEK‐Inhibitor in a patient with NRAS‐Related cutaneous Skeletal Hypophosphatemia syndrome | |
Qiao et al. | Gene expression profiling in a mouse model of infantile neuronal ceroid lipofuscinosis reveals upregulation of immediate early genes and mediators of the inflammatory response | |
Goldbergova et al. | Association of two angiotensinogen gene polymorphisms, M235T and G (–6) A, with chronic heart failure | |
Fountain et al. | Kv1. 5 potassium channel gene regulation by Sp1 transcription factor and oxidative stress | |
Taylor et al. | Ribozyme compromise of adrenomedullin mRNA reveals a physiological role in the regulation of water intake | |
US20020162125A1 (en) | Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal | |
Dorn 2nd | Neurohormonal connections with mitochondria in cardiomyopathy and other diseases | |
CN112512519B (zh) | 治疗致密化不全心肌症的方法 | |
Skelding et al. | Sympathomimetics in veterinary species under anesthesia | |
Szentirmai et al. | Growth hormone-releasing hormone: cerebral cortical sleep-related EEG actions and expression | |
Hasan et al. | Modulation of rat parasympathetic cardiac ganglion phenotype and NGF synthesis by adrenergic nerves | |
Patrizio et al. | cAMP-mediated β-adrenergic signaling negatively regulates Gq-coupled receptor-mediated fetal gene response in cardiomyocytes | |
Ishikawa et al. | Verification of the effectiveness of an SNP marker in the cholecystokinin type A receptor gene for improving growth traits in Okumino-kojidori chickens | |
Elmeligy et al. | Effect of magnesium sulfate nebulization on stress response induced tracheal intubation; Prospective, randomized study |